Response to Crudele Et Al. Commentary on Gudin Et Al. "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties"
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Perrino P, Colucci S, Apseloff G, Harris S
. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. Clin Drug Investig. 2013; 33(6):441-9.
PMC: 3664752.
DOI: 10.1007/s40261-013-0085-x.
View
2.
Pergolizzi Jr J, Taylor Jr R, Nalamachu S, Raffa R, Carlson D, Varanasi R
. Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. Curr Med Res Opin. 2013; 30(2):191-202.
DOI: 10.1185/03007995.2013.854197.
View
3.
Kopecky E, Fleming A, Noonan P, Varanasi R, Grima M, Saim S
. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation. J Opioid Manag. 2014; 10(4):233-46.
DOI: 10.5055/jom.2014.0211.
View
4.
Gudin J, Levy-Cooperman N, Kopecky E, Fleming A
. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. Pain Med. 2015; 16(11):2142-51.
DOI: 10.1111/pme.12834.
View